Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Editorial Board262
Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis198
Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming177
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer161
Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors141
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review124
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty116
The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology95
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis94
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer93
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer93
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)81
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in80
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials77
Proton therapy in breast cancer: bridging medical and radiation oncology75
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives75
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches68
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis68
Editorial Board61
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma59
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era58
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?57
If it’s a target, it’s a pan-cancer target: Tissue is not the issue55
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment55
Emerging antibody-based therapies for the treatment of acute myeloid leukemia54
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.54
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications53
Revisiting patient preference in resectable and irradiable stage III NSCLC in the immunotherapy era53
Optimizing care in early phase cancer trials: The role of palliative care53
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC51
De-escalation strategies with targeted therapies in non-small cell lung cancer51
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials51
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment51
Editorial Board50
Editorial Board50
Uncertainties and controversies in axillary management of patients with breast cancer50
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes49
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?48
Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation48
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?47
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation47
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy47
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck47
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis46
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations46
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier43
Extracellular vesicles and the “six Rs” in radiotherapy43
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review41
Corrigendum to “The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management”. [Cancer Treat. Rev. 139 (2025) 102998]41
Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working group (TARPSWG)41
Editorial Board41
The immunogram of inflammatory breast cancer40
Overview of BH3 mimetics in ovarian cancer39
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis38
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada38
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design38
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features38
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside36
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers36
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma35
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma34
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review33
Long-term surveillance recommendations for young adult cancer survivors33
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)33
Expanding the therapeutic Frontier: Liver transplantation for unresectable colorectal liver metastases32
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies32
Editorial Board32
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review32
Assessing lung function in women treated for breast cancer with radiotherapy. A comprehensive systematic review and meta-analysis31
Systematic review of the CUP trials characteristics and perspectives for next-generation studies31
Immunocytokines in cancer treatment: A systematic review31
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer31
Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review30
Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials30
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer30
Malignant ascites: Current therapy options and treatment prospects29
Editorial Board29
Bone complications of cancer treatment29
Editorial Board29
Agnostic drug development revisited29
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life29
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review29
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review28
Corrigendum to “T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis”. [Cancer Treat Rev. 139 (2025) 102991. doi: 10.1016/j.ctrv.2025.102991]28
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review28
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?27
Genomic distinctions in adolescent and young adult cancer: A comprehensive review27
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review27
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers27
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification26
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges26
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review26
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes26
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis26
Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review25
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie25
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?25
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project25
Local control strategies for management of NSCLC with oligoprogressive disease25
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives25
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis24
Strategies for improving detection of circulating tumor DNA using next generation sequencing24
Management of infections in the outpatient care of patients with cancer24
Evolving immunotherapeutic solutions for triple-negative breast carcinoma24
Review: Targeting EZH2 in neuroblastoma23
Pharmacotherapy for leptomeningeal disease in breast cancer23
Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies23
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer23
Editorial Board23
Engineering strategies to optimise adoptive cell therapy in ovarian cancer23
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis23
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]23
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review22
Diagnostic utility of urinary cell-free DNA in non-urothelial cancer: a systematic review, meta-analysis, & network meta-analysis22
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment22
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis22
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives22
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies22
Editorial Board22
Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non–small cell lung cancer21
Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy21
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications21
Ex vivo drug screening on patient-derived tumor material to advance functional precision in oncology: an overview on current approaches and unresolved challenges21
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression21
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review21
0.4160430431366